• PharmAbcine, SLBio Enter NSCLC Research Pact contractpharma
    August 04, 2020
    To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.
PharmaSources Customer Service